An observational study in Acute Hemorrhagic Stroke, sponsored by Beijing Tiantan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Beijing Tiantan Hospital · Observational
Acute hemorrhagic cerebrovascular disease is a life-threatening condition characterized by sudden onset, rapid progression, multiple complications, poor prognosis, and high mortality. It presents a significant public health burden. During surgical interventions, precise risk stratification and effective perioperative management are crucial to mitigating intraoperative and postoperative complications, optimizing disease diagnosis, guiding severity assessment, and refining anesthesia strategies. Continuous real-time evaluation and dynamic perioperative adjustments are essential to minimize the influence of institutional variability and individual clinician-dependent decision-making. By harnessing big data-driven, evidence-based medical approaches, clinicians can enhance diagnostic accuracy and therapeutic precision, addressing a critical challenge in reducing morbidity and mortality in this patient population.
This study aims to develop a comprehensive multimodal perioperative database and leverage large language models (LLMs) for the efficient extraction of structured demographic and clinical data throughout the perioperative course. By integrating real-time hemodynamic monitoring parameters, the investigators seek to elucidate the relationship between perioperative hemodynamic patterns and the incidence of postoperative complications affecting major organ systems, including the brain, heart, kidneys, and lungs. The ultimate goal is to construct a multimodal fusion early-warning model capable of real-time, simultaneous prediction of multiple perioperative complications. This AI-driven platform will function as a risk stratification and alert system for organ-specific perioperative complications in patients with acute hemorrhagic cerebrovascular disease. By providing evidence-based insights for optimized perioperative management-encompassing early warning mechanisms, diagnostic support, and individualized therapeutic strategies-the system aims to improve clinical outcomes, reduce perioperative morbidity, and lower overall mortality.
Beijing Tiantan Hospital is the lead sponsor of 483 studies on the registry; 289 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The investigators plan to recruit patients aged 18-80 years with acute hemorrhagic cerebrovascular disease from a minimum of three tertiary Grade A general hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The primary outcome measures were postoperative complications involving the neurological, cardiac, pulmonary, and renal systems in patients with acute hemorrhagic cerebrovascular disease following surgical interventions.
Time frame: Within 30 days after surgery
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jul 2025; primary completion for Dec 2027, 29 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.